title: Hepatitis C infection in HIV-1 natural viral suppressors.
abstract: OBJECTIVE
  HIV-1 natural viral suppressors (NVSs) demonstrate an intrinsic ability to control HIV-1 replication in the absence of antiretroviral therapy. The objective of this study was to investigate whether HIV-infected NVSs also demonstrate enhanced ability to control hepatitis C virus (HCV) infection, and whether HCV infection in the NVSs affects the degree of HIV control.
  
  
  METHODS
  A cross-sectional study was undertaken to compare HCV-related parameters in the NVS to the two race-matched cohorts (HIV/HCV-coinfected or HCV-monoinfected patients). Within the NVS, HIV-related parameters were compared based on the presence or absence of chronic HCV.
  
  
  RESULTS
  NVS patients had a significantly higher clearance rate of HCV at 23.3% (seven of 30), compared to the 6.5% (23 of 350) of HIV/HCV-coinfected and 9.1% (32 of 350) of HCV-monoinfected patients (P = 0.005 and P = 0.024, respectively). Apart from the HCV clearance rate, there was no significant difference in HCV-related parameters such as HCV viral load or liver histology in the NVS with chronic HCV compared to HCV/HIV-coinfected patients or HCV-monoinfected patients. However, NVS patients with chronic HCV infection had statistically significant lower CD4 cell count and CD4%, and lower CD4/CD8 ratio compared to those NVSs without chronic HCV infection (P = 0.029, P = 0.046, and P = 0.062, respectively).
  
  
  CONCLUSIONS
  It appears that some NVS patients have the ability to effectively control multiple agents that can cause chronic viral infections. In addition, it appears that the presence of chronic HCV infection within the NVS adversely affects immunological parameters.
authors.affiliation: Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. msajadi@ihv.umaryland.edu
authors.forename: Mohammad M
authors.initials: MM
authors.lastname: Sajadi
authors.forename: Nahzinine
authors.initials: N
authors.lastname: Shakeri
authors.forename: Rohit
authors.initials: R
authors.lastname: Talwani
authors.forename: Robert R
authors.initials: RR
authors.lastname: Redfield
mesh_terms: D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000276:immunology / Q000821:virology*; D020276:HIV Long-Term Survivors; D015497:HIV-1 / Q000302:isolation & purification / Q000502:physiology*; D016174:Hepacivirus / Q000302:isolation & purification / Q000502:physiology; D006526:Hepatitis C / Q000150:complications / Q000276:immunology / Q000821:virology*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000276:immunology / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D019562:Viral Load; D014779:Virus Replication
references.citation: J Virol. 2006 May;80(10):4758-70
references.pmid: 16641269
references.citation: JAMA. 2002 Jul 10;288(2):199-206
references.pmid: 12095384
references.citation: AIDS. 2007 Feb 19;21(4):517-9
references.pmid: 17301571
references.citation: J Infect Dis. 2009 Sep 15;200(6):984-90
references.pmid: 19656066
references.citation: Virology. 1998 May 10;244(2):504-12
references.pmid: 9601518
references.citation: Hepatology. 1999 Oct;30(4):1054-8
references.pmid: 10498659
references.citation: Clin Infect Dis. 2009 Aug 15;49(4):612-22
references.pmid: 19591597
references.citation: AIDS. 1995 Oct;9(10):1131-6
references.pmid: 8519448
references.citation: J Infect Dis. 1996 Oct;174(4):690-5
references.pmid: 8843204
references.citation: J Infect Dis. 2007 Nov 15;196(10):1474-82
references.pmid: 18008226
references.citation: AIDS Res Hum Retroviruses. 2007 Jul;23(7):863-7
references.pmid: 17678468
references.citation: J Infect Dis. 2008 Feb 15;197(4):563-71
references.pmid: 18275276
references.citation: Hepatology. 2001 Dec;34(6):1193-9
references.pmid: 11732009
references.citation: Clin Infect Dis. 2006 Nov 1;43(9):1209-12
references.pmid: 17029144
references.citation: Lancet. 2000 Nov 25;356(9244):1800-5
references.pmid: 11117912
references.citation: Gut. 2006 Aug;55(8):1183-7
references.pmid: 16434426
references.citation: AIDS. 2002 Apr 12;16(6):813-28
references.pmid: 11919483
references.citation: Arch Intern Med. 2002 Oct 14;162(18):2125-32
references.pmid: 12374521
references.citation: Clin Infect Dis. 2005 Oct 1;41(7):1053-6
references.pmid: 16142675
references.citation: JAMA. 2000 Jul 26;284(4):450-6
references.pmid: 10904508
references.citation: Can J Gastroenterol. 2007 Jul;21(7):447-51
references.pmid: 17637948
references.citation: J Viral Hepat. 2006 Jan;13(1):34-41
references.pmid: 16364080
references.citation: Clin Infect Dis. 2001 Aug 15;33(4):562-9
references.pmid: 11462196
references.citation: Nature. 2009 Oct 8;461(7265):798-801
references.pmid: 19759533
references.citation: J Infect Dis. 2009 Oct 15;200(8):1216-26
references.pmid: 19764883
references.citation: J Clin Virol. 2007 Jun;39(2):82-6
references.pmid: 17434339
references.citation: J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):403-8
references.pmid: 19214118
references.citation: Clin Infect Dis. 2007 Feb 1;44(3):431-7
references.pmid: 17205454
references.citation: J Med Virol. 2007 May;79(5):503-10
references.pmid: 17385690
references.citation: Vox Sang. 1995;69(3):259-60
references.pmid: 8578743